Omega Common Stock vs Current Deferred Revenue Analysis

OMGA Stock

USD 0.86 0.07 8.86%

Omega Therapeutics financial indicator trend analysis is much more than just breaking down Omega Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Omega Therapeutics is a good investment. Please check the relationship between Omega Therapeutics Common Stock and its Current Deferred Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omega Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.

Common Stock vs Current Deferred Revenue

Common Stock vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Omega Therapeutics Common Stock account and Current Deferred Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Omega Therapeutics' Common Stock and Current Deferred Revenue is -0.98. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Omega Therapeutics, assuming nothing else is changed. The correlation between historical values of Omega Therapeutics' Common Stock and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Omega Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Common Stock i.e., Omega Therapeutics' Common Stock and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.98

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Common Stock

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Omega Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Omega Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omega Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.At present, Omega Therapeutics' Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 301.7 M, whereas Selling General Administrative is forecasted to decline to about 16.5 M.

	2021	2022	2023	2024 (projected)
Interest Expense	910K	222K	199.8K	189.8K
Depreciation And Amortization	1.4M	5.2M	6.8M	7.1M

Interest Expense Depreciation And Amortization

Omega Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.63	0.43	0.88	0.93	-0.84	0.97	0.59	-0.41	-0.83	0.81	0.93	0.61	0.31	-0.94	0.88	0.91	0.67	0.97	0.58	0.25	0.81	0.96	0.45	0.93	0.61
Short Long Term Debt Total	0.63		-0.34	0.74	0.39	-0.82	0.62	1.0	0.42	-0.9	0.39	0.4	1.0	-0.03	-0.74	0.42	0.37	0.99	0.62	1.0	0.66	0.64	0.66	0.76	0.4	1.0
Other Current Liab	0.43	-0.34		0.31	0.63	-0.24	0.44	-0.38	-0.83	-0.1	0.71	0.57	-0.32	0.72	-0.28	0.54	0.55	-0.24	0.47	-0.41	-0.52	0.41	0.44	-0.35	0.63	-0.35
Total Current Liabilities	0.88	0.74	0.31		0.7	-0.96	0.8	0.71	-0.05	-0.95	0.82	0.65	0.75	0.51	-0.8	0.64	0.6	0.8	0.93	0.7	0.47	0.97	0.95	0.67	0.71	0.73
Total Stockholder Equity	0.93	0.39	0.63	0.7		-0.69	0.96	0.34	-0.63	-0.65	0.84	0.96	0.37	0.39	-0.87	0.98	0.95	0.43	0.89	0.32	-0.12	0.69	0.84	0.09	1.0	0.37
Other Liab	-0.84	-0.82	-0.24	-0.96	-0.69		-0.82	-0.79	-0.04	0.99	-0.84	-0.63	-0.83	-0.5	0.84	-0.67	-0.59	-0.88	-0.88	-0.77	-0.39	-0.94	-0.92	-0.59	-0.7	-0.81
Net Tangible Assets	0.97	0.62	0.44	0.8	0.96	-0.82		0.58	-0.42	-0.81	0.83	0.93	0.6	0.32	-0.95	0.95	0.92	0.66	0.94	0.56	0.09	0.77	0.9	0.29	0.97	0.6
Property Plant And Equipment Net	0.59	1.0	-0.38	0.71	0.34	-0.79	0.58		0.47	-0.87	0.35	0.35	1.0	-0.06	-0.7	0.37	0.32	0.99	0.58	1.0	0.69	0.61	0.63	0.77	0.35	1.0
Net Debt	-0.41	0.42	-0.83	-0.05	-0.63	-0.04	-0.42	0.47		-0.12	-0.41	-0.66	0.45	-0.23	0.29	-0.55	-0.69	0.39	-0.33	0.48	0.53	-0.06	-0.29	0.44	-0.62	0.44
Retained Earnings	-0.83	-0.9	-0.1	-0.95	-0.65	0.99	-0.81	-0.87	-0.12		-0.75	-0.61	-0.91	-0.37	0.86	-0.64	-0.57	-0.94	-0.86	-0.86	-0.49	-0.9	-0.9	-0.67	-0.67	-0.89
Accounts Payable	0.81	0.39	0.71	0.82	0.84	-0.84	0.83	0.35	-0.41	-0.75		0.74	0.42	0.78	-0.74	0.8	0.7	0.49	0.86	0.32	-0.1	0.88	0.86	0.14	0.85	0.38
Cash	0.93	0.4	0.57	0.65	0.96	-0.63	0.93	0.35	-0.66	-0.61	0.74		0.37	0.21	-0.91	0.9	1.0	0.42	0.84	0.33	0.0	0.58	0.84	0.17	0.96	0.38
Non Current Assets Total	0.61	1.0	-0.32	0.75	0.37	-0.83	0.6	1.0	0.45	-0.91	0.42	0.37		0.03	-0.72	0.4	0.33	1.0	0.62	0.99	0.66	0.67	0.66	0.76	0.38	1.0
Non Currrent Assets Other	0.31	-0.03	0.72	0.51	0.39	-0.5	0.32	-0.06	-0.23	-0.37	0.78	0.21	0.03		-0.17	0.37	0.16	0.09	0.47	-0.08	-0.3	0.69	0.44	-0.11	0.4	-0.03
Other Assets	-0.94	-0.74	-0.28	-0.8	-0.87	0.84	-0.95	-0.7	0.29	0.86	-0.74	-0.91	-0.72	-0.17		-0.83	-0.89	-0.76	-0.87	-0.68	-0.27	-0.71	-0.91	-0.45	-0.87	-0.72
Long Term Debt	0.88	0.42	0.54	0.64	0.98	-0.67	0.95	0.37	-0.55	-0.64	0.8	0.9	0.4	0.37	-0.83		0.89	0.46	0.85	0.35	-0.2	0.66	0.76	0.01	0.98	0.4
Cash And Short Term Investments	0.91	0.37	0.55	0.6	0.95	-0.59	0.92	0.32	-0.69	-0.57	0.7	1.0	0.33	0.16	-0.89	0.89		0.39	0.8	0.31	-0.03	0.53	0.8	0.14	0.95	0.35
Net Receivables	0.67	0.99	-0.24	0.8	0.43	-0.88	0.66	0.99	0.39	-0.94	0.49	0.42	1.0	0.09	-0.76	0.46	0.39		0.67	0.98	0.63	0.72	0.72	0.75	0.45	0.99
Common Stock Total Equity	0.97	0.62	0.47	0.93	0.89	-0.88	0.94	0.58	-0.33	-0.86	0.86	0.84	0.62	0.47	-0.87	0.85	0.8	0.67		0.56	0.24	0.91	0.96	0.46	0.9	0.6
Common Stock Shares Outstanding	0.58	1.0	-0.41	0.7	0.32	-0.77	0.56	1.0	0.48	-0.86	0.32	0.33	0.99	-0.08	-0.68	0.35	0.31	0.98	0.56		0.71	0.6	0.61	0.79	0.33	1.0
Non Current Liabilities Total	0.25	0.66	-0.52	0.47	-0.12	-0.39	0.09	0.69	0.53	-0.49	-0.1	0.0	0.66	-0.3	-0.27	-0.2	-0.03	0.63	0.24	0.71		0.29	0.36	0.97	-0.11	0.67
Other Current Assets	0.81	0.64	0.41	0.97	0.69	-0.94	0.77	0.61	-0.06	-0.9	0.88	0.58	0.67	0.69	-0.71	0.66	0.53	0.72	0.91	0.6	0.29		0.9	0.51	0.7	0.64
Other Stockholder Equity	0.96	0.66	0.44	0.95	0.84	-0.92	0.9	0.63	-0.29	-0.9	0.86	0.84	0.66	0.44	-0.91	0.76	0.8	0.72	0.96	0.61	0.36	0.9		0.56	0.85	0.65
Total Liab	0.45	0.76	-0.35	0.67	0.09	-0.59	0.29	0.77	0.44	-0.67	0.14	0.17	0.76	-0.11	-0.45	0.01	0.14	0.75	0.46	0.79	0.97	0.51	0.56		0.1	0.77
Net Invested Capital	0.93	0.4	0.63	0.71	1.0	-0.7	0.97	0.35	-0.62	-0.67	0.85	0.96	0.38	0.4	-0.87	0.98	0.95	0.45	0.9	0.33	-0.11	0.7	0.85	0.1		0.38
Property Plant And Equipment Gross	0.61	1.0	-0.35	0.73	0.37	-0.81	0.6	1.0	0.44	-0.89	0.38	0.38	1.0	-0.03	-0.72	0.4	0.35	0.99	0.6	1.0	0.67	0.64	0.65	0.77	0.38

Click cells to compare fundamentals

Omega Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Omega Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Omega Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Omega Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Omega Therapeutics Stock:

How To Invest In Omega

Details

Is Omega Stock a good investment?

Details

What is Omega Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omega Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For information on how to trade Omega Stock refer to our How to Trade Omega Stock guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.32)

Revenue Per Share

0.114

Quarterly Revenue Growth

1.812

Return On Assets

(0.25)

Return On Equity

(1.29)

The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Omega Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Omega Common Stock vs Current Deferred Revenue Analysis

Common Stock vs Current Deferred Revenue

Common Stock vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Common Stock

Current Deferred Revenue

Omega Therapeutics fundamental ratios Correlations

Omega Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Common Stock Shares Outstanding	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net

Other Liab	- 0.96	Total Current Liabilities
Other Assets	- 0.95	Net Tangible Assets
Retained Earnings	- 0.95	Total Current Liabilities
Net Receivables	- 0.94	Retained Earnings
Other Current Assets	- 0.94	Other Liab
Other Assets	- 0.94	Total Assets